Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF.

[1]  G. Lip,et al.  Stroke Prevention in Atrial Fibrillation: Focus on Latin America , 2016, Arquivos brasileiros de cardiologia.

[2]  E. Antman,et al.  Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial. , 2018, Journal of the American College of Cardiology.

[3]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[4]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[5]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[6]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[7]  Á. Avezum,et al.  Stroke in Latin America: Burden of Disease and Opportunities for Prevention. , 2015, Global heart.

[8]  R. Harrington,et al.  Disaggregation of Cause-Specific Cardiovascular Disease Mortality Among Hispanic Subgroups , 2017, JAMA cardiology.

[9]  F. Lanas,et al.  Coronary heart disease and risk factors in latin america. , 2013, Global heart.

[10]  A. Go,et al.  Effect of Race/Ethnicity on the Efficacy of Warfarin , 2008, CNS drugs.

[11]  Hugh Calkins,et al.  Correction to: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Circulation.

[12]  Gregory Y H Lip,et al.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.

[13]  M. R. Botton,et al.  Pharmacogenetics of coumarin anticoagulants in Brazilians , 2015, Expert opinion on drug metabolism & toxicology.

[14]  I. Piña,et al.  Status of Cardiovascular Disease and Stroke in Hispanics/Latinos in the United States: A Science Advisory From the American Heart Association , 2014, Circulation.

[15]  W. Haskell,et al.  Association of Educational Attainment and Cardiovascular Risk in Hispanic Individuals: Findings From the Cooper Center Longitudinal Study , 2019, JAMA cardiology.

[16]  P. Perel,et al.  Major Cardiovascular Risk Factors in Latin America: A Comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO) , 2013, PloS one.

[17]  R. Investigators.  Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. , 2010, American heart journal.

[18]  G. Silva,et al.  Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective , 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[19]  G. Lip,et al.  Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report , 2012, Chest.

[20]  R. Harrington,et al.  Nativity Status and Cardiovascular Disease Mortality Among Hispanic Adults , 2017, Journal of the American Heart Association.

[21]  C. Martinez,et al.  XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America , 2018, The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology.

[22]  K. Pieper,et al.  Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry , 2019, Clinical cardiology.

[23]  J. Piccini,et al.  International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. , 2012, American heart journal.

[24]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[25]  J. Johnson,et al.  Warfarin Pharmacogenetics: An Illustration of the Importance of Studies in Minority Populations , 2014, Clinical pharmacology and therapeutics.